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ABSTRACT
Dormant leukaemia initiating cells in the bone marrow niche are a crucial 
therapeutic target for total eradication of acute myeloid leukaemia. To study this 
cellular subset we created and validated an in vitro model employing the cell line TF-
1a, treated with Transforming Growth Factor β1 (TGFβ1) and a mammalian target of 
rapamycin inhibitor. The treated cells showed decreases in total RNA, Ki-67 and CD71, 
increased aldehyde dehydrogenase activity, forkhead box 03A (FOX03A) nuclear 
translocation and growth inhibition, with no evidence of apoptosis or differentiation. 
Using human genome gene expression profiling we identified a signature enriched 
for genes involved in adhesion, stemness/inhibition of differentiation and tumour 
suppression as well as canonical cell cycle regulation. The most upregulated gene 
was the osteopontin-coding gene SPP1. Dormant cells also demonstrated significantly 
upregulated beta 3 integrin (ITGB3) and CD44, as well as increased adhesion to 
their ligands vitronectin and hyaluronic acid as well as to bone marrow stromal 
cells. Immunocytochemistry of bone marrow biopsies of AML patients confirmed the 
positive expression of osteopontin in blasts near the para-trabecular bone marrow, 
whereas osteopontin was rarely detected in mononuclear cell isolates. Unsupervised 
hierarchical clustering of the dormancy gene signature in primary acute myeloid 
leukaemia samples from the Cancer Genome Atlas identified a cluster enriched for 
dormancy genes associated with poor overall survival.
INTRODUCTION
Acute myeloid leukaemia (AML) is characterised 
by a high disease relapse rate despite initial induction 
of remission. The leukaemia-initiating cells (LIC) that 
survive chemotherapy are likely to be enriched for a 
dormant subpopulation within the bone marrow niche 
[1]. Dormancy is a non-proliferative state where cells 
stay outside the cell cycle but retain their proliferative 
potential, in contrast to the terminally non-proliferative 
differentiated cell. The study and characterization of 
dormant LICs could pave the way to their targeting and 
eradication, but the simple paradox that these rare dormant 
cells cannot be expanded for research without breaking 
their dormancy suggests that efforts need to be directed to 
establish experimental models of induced dormancy.
The crosstalk between LICs and the bone marrow 
(BM) niche in which they reside has been implicated 
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in dormancy regulation. Leukaemia cells which are 
responsible for relapsed AML, similar to normal 
haematopoietic stem cells (HSCs), reside in a low 
perfusion microenvironment in the endosteal region 
of the bone marrow [2–4]. The scarcity of nutrients 
in the poorly-perfused niche is likely to contribute to 
leukaemia cell dormancy and resistance to chemotherapy. 
MTOR inhibition by rapamycin can be used to mimic 
shortage of nutrients [5, 6], and has been employed for 
the in vitro maintenance of haematopoietic stem cells 
[7]. Furthermore, it has been reported that mTOR-
inhibited leukaemia cell lines [8] and prostatic cancer 
cells [9] showed features of dormancy and resistance 
to chemotherapy. TGFβ1 is strongly involved in the 
regulation of dormancy in normal undifferentiated HSC 
[10]. The addition of mTOR inhibition to TGFβ1 was 
reported to potentiate the inhibitory effect of TGFβ1 in 
transformed cells [11].
The current study aimed to exploit the above two 
key BM LIC niche characteristics – i.e. the abundance of 
TGFβ1 and shortage of nutrients, to establish an in vitro 
model that enables molecular characterization of dormant 
AML cells. Some AML clones are dependent on aberrant 
activation of the mTOR pathway for survival and hence 
sensitive to clinical mTOR inhibitors, but other clones 
are resistant [12], and in this study we characterise a 
cell line (TF-1a) which remained viable in the presence 
of rapamycin and in which we were able to exploit the 
dormancy-inducing physiological role of mTOR inhibition 
[13]. This work is a step towards the ultimate goal of 
finding molecular targets that might help to eradicate 
dormant LICs and hence prevent relapse.
RESULTS
TGFβ1 and mTOR pathway inhibition 
significantly impede TF-1a cell proliferation 
and induce features of dormancy and stemness 
without affecting cell viability or inducing cell 
differentiation
TF-1a cells were cultured with 4ng/ml TGFβ1 and/
or 100nM rapamycin. Clonogenic growth was inhibited by 
TGFβ1 or rapamycin individually, and the combination of 
the two agents blocked the formation of colonies (>95% 
inhibition, Figure 1A). Growth inhibition in suspension 
culture (Figure 1B) was accompanied by features of 
dormancy including an increase in the proportion of Ki-
67 negative cells (p < 0.01) (Figure 1C) and a decrease 
in RNA, characteristic of dormant cells due to their low 
metabolic activity (Figure 1D). In addition, a significant 
decrease in the transferrin receptor and proliferation 
marker CD71 was evident (Figure 1E). TGFβ1+rapamycin 
treatment showed no effect on the viability of TF-1a 
cells as determined by annexinV flow cytometry assay 
(Supplementary Figure 1), excluding cellular death as a 
possible explanation for the growth inhibition. The cellular 
potential to proliferate decreases in the haematopoietic 
cell hierarchy as cells differentiate. However, following 
conditioning with TGFβ1 and/or rapamycin, TF-1a 
cells maintained a primitive morphology with no signs 
of differentiation (Supplementary Figure 2). TGFβ1 is 
reported to upregulate the stem-like properties of HSC 
[14] and LIC [15], and AML cells with intermediate 
ALDH activity are reported to be highly represented in 
minimal residual disease AML samples [16]. TGFβ1 
upregulated ALDH activity and surface CD34 expression 
in TF-1a cells. Of note, although CD34 expression 
ranges from negative to positive in untreated TF-1a cells 
the treated cells became >90% CD34+ (Figure 1F and 
Supplementary Figure 3). Relocation of FOXO3a from 
cytoplasm to nucleus, suggestive of activation, was also 
seen (Figure 1F). Growth-inhibitory responses of KG-1a, 
Kasumi-3 and M0-91 cells to TGFβ1 were also measured 
as well as their CD34 and CD38 status (Supplementary 
Figure 3). The growth-inhibitory response to TGFβ1 
noted in TF-1a cells compared to KG-1a and Kasumi-3 
cells and the pronounced loss of Ki-67 in TF-1a after 
TGFβ1 treatment compared to Kasumi-3 and M0-91 cells 
supported its selection to model and characterize AML cell 
dormancy in the study.
Molecular signature of TF-1a cells induced to 
dormancy
Dormancy-induced TF-1a cells were subjected 
to molecular characterization by microarray analysis. 
Restricting the dormancy signature to genes upregulated 
or downregulated by at least 2 fold with false discovery 
rate (FDR)-adjusted p value <0.05, we found 240 
upregulated genes and 136 downregulated genes in 
dormant TF-1a cells compared to their untreated (cycling) 
counterparts (Figure 2 and Supplementary Figure 4). 
A full list of the differentially regulated genes can be 
found in Supplementary Tables 1 and 2) and a copy of 
the complete results have been deposited in the gene 
expression omnibus database, (http://www.ncbi.nlm.nih.
gov/geo/), reference GSE102483. As is clear from Figure 
2, TGFβ1 alone contributes much more strongly to gene 
upregulation than rapamycin, but the disparity is not as 
strong in downregulated genes.
Among the 240 differentially upregulated and 136 
downregulated genes in dormant TF-1a cells, we identified 
canonical targets of TGFB1 and of mTOR inhibition 
(Supplementary Table 3). We found three biologically 
relevant groups of genes highly represented in the 
dormancy signature. These were adhesion-related, tumour 
suppressor and stemness / inhibition of differentiation-
related genes (Figure 3). The categories overlap: for 
example, amongst the adhesion related genes, ITGB3 [17] 
and CD44 [18] are also essential for the maintenance of 
leukaemia initiating cells.
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Figure 1: Dormancy induction in TF-1a cells. (A) Clonogenic assays were carried out in a methylcellulose-based medium (H4100 
from Stem cell Technologies) using standard procedures, with TF-1a cells seeded at 200 cells per 100 μl in triplicate in 96-well plates 
with 4ng/ml TGFβ1 and/or 100nM rapamycin. Large colonies (solid upper bars, >50 cells) and smaller colonies (striped lower bars, 20-50 
cells) were counted after 6 days. (B) Inhibition of growth in suspension culture. Cells were seeded at a concentration of 2x10^5 cells/ml 
and incubated for 72 hrs with 4ng/ml TGFβ1 and/or 100nM rapamycin before counting. (C) Cells were cultured for 3 days as in B: flow 
cytometric histograms of Ki-67 expression. Isotype control (grey histograms) are used as a reference to determine the percentage of Ki-67 
negative cells. (D) Cells were cultured for 3 days as in B. Total RNA content was measured using a nanodrop. (E) Cells were cultured for 
3 days as in B: surface CD71 expression measured by flow cytometry. (F) Modulation of stemness markers by TGFβ1: ALDH (i), CD34 
(ii) and FOXO3a (iii). In A, B, D and E, the columns represent mean +/- SD of three independent experiments (*: p < 0.05; **: p < 0.01). In 
C and F, the figures are representative examples of 3 biological replicates.
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Integrin and cell adhesion signalling pathways 
dominate the biological processes enriched in the 
molecular signature of dormant AML cells
To group the detected genes based on their gene 
ontology (GO) categories into relevant biological 
processes, gene enrichment analysis was performed (in 
Partek) using the Kyoto Encyclopaedia of Genes and 
Genomes (KEGG) database. Information was available on 
195 of the 240 upregulated genes, and these mapped to 56 
distinct biologically relevant groups (Supplementary Table 
4). Among these, the integrin-mediated and cell adhesion 
signalling pathways showed the highest enrichment 
scores; 14.43 and 13.41 respectively (p<0.001 for both). 
Confirmation of adhesion-related gene upregulation was 
obtained by quantitative PCR (Figure 4). Information 
on 100/136 downregulated genes was available and 
these were mapped to 46 significantly enriched distinct 
biologically relevant groups (Supplementary Table 5). 
Downregulated genes were dominated by alterations in 
metabolic pathways.
Figure 2: Heat maps of differentially regulated genes in dormant TF-1a cells. TF-1a cells were cultured for 3 days with 4ng/ml 
TGFβ1 and/or 100nM rapamycin prior to gene expression profiling. The heat maps illustrate (A) The top 60 of the 240 most significantly 
upregulated genes and (B) the top 60 of the 136 most downregulated genes. UT: untreated; RA: rapamycin; TG: TGFβ1.
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Osteopontin is expressed in AML bone marrow 
and its expression is stimulated by TGFβ1 in 
primary samples
SPP1, the gene encoding osteopontin, showed the 
highest fold upregulation in our model. However levels 
(even though significantly upregulated) were low and 
attempts at protein detection in the model were unreliable. 
A meta-analysis of several studies indicates that serum 
osteopontin (OPN) is a marker of poor survival and a 
Figure 3: Biologically related groups of genes in dormant TF-1a cells. Mean values for fold upregulation (red bars) or 
downregulation (blue bars).
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potential therapeutic target in AML patients [19]. We 
therefore looked for the presence of osteopontin in primary 
AML patient material. Osteopontin protein was detected 
in the blast cell cytoplasm of both presentation and post-
treatment BM biopsies from 7/7 patients (patient details in 
Supplementary Table 6). 2 of the biopsies showed stronger 
OPN expression in the cytoplasm of blasts adjacent 
to the bone trabeculae in comparison to those further 
from this area of the BM (Figure 5A). The other 5 cases 
showed a similar pattern of OPN expression regardless 
the anatomical localization of the leukaemia cells (e.g. 
Supplementary Figure 5). We also measured SPP1 
message in 13 primary AML mononuclear cell isolates. In 
10/13, SPP1 expression was undetectable (Supplementary 
Figure 6), strongly suggesting the necessity for exogenous 
factors present in the bone marrow microenvironment such 
as TGFβ1 to induce expression. Indeed SPP1 expression 
was induced by in vitro culture with TGFβ1 in 5/5 samples 
(Figure 5B).
Protein and functional validation of adhesion 
proteins in AML cells
As genes involved in integrin-mediated signalling 
and adhesion were markedly enriched in the signature of 
dormant AML cells, we further characterised the most 
upregulated integrin – integrin beta 3 (ITGB3, CD61) 
and its binding partner integrin alpha v (ITGAV, CD51). 
We found upregulation of CD61 (p=0.01) and CD51 
protein expression (p=0.005) in the dormancy-enriched 
cells (Figure 6A). CD44, a gene found in the dormancy 
expression profile which interacts with ITGB3 and 
osteopontin to mediate adhesion and signalling (reviewed 
in [20] and [21]), was also upregulated at the protein level 
(p=0.01).
We also examined the adhesive properties of the 
dormancy-enriched TF-1a cells (Figure 6B), which 
demonstrated significantly enhanced adhesion to the 
stromal cell line HS-5 (p=0.03). Dormant cells were 
also more adherent than cycling cells to immobilised 
vitronectin (fold increase 2.5; p=0.02) and hyaluronic 
acid (fold increase = 2.4; p=0.02), (ligands of integrin B3 
and CD44 respectively). As expected from the literature 
on this topic, fibronectin elicited strong adhesion [22], but 
this was not increased in dormant cells.
Molecular signatures of dormancy in patient 
samples
Publically available data from the Cancer Genome 
Atlas (TCGA) [23, 24] on 149 cases of AML (excluding 
patients with a t(15;17) translocation, but comprising all 
other patients with documented outcome data) was studied 
to determine whether there is a particular subset of AML 
patients with a strong intrinsic dormancy signature. Using 
unsupervised hierarchical clustering, we selected the 240 
upregulated and 136 downregulated genes identified in 
our model, from which we mapped five clusters of genes 
and four clusters of patients (Figure 7A). A fifth patient 
cluster comprising a single case was excluded from 
the analysis. Using Fisher’s exact test we determined 
significant enrichment for adhesion in gene cluster 5 
Figure 4: qPCR validation. Expression of the 7 top significantly upregulated adhesion-related genes in dormant TF-1a cells. 
SPP1 and ITGA3 genes are highlighted in red as their baseline expression was negligible, in contrast to the other genes where 
the increase was indicative of upregulation. Mean +/- SD of three independent experiments. * p value<0.05, ** p value<0.01.
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Figure 5: Osteopontin expression in AML patients. (A) Osteopontin expression in a bone marrow biopsy from an AML patient. 
Picture (ii) shows magnification of the rectangular area from picture (i) to illustrate the cytoplasmic expression in leukemic blasts. B, blast. 
BT, bone trabecula. E, erythroid cell. M, megakaryocyte. (iii) No primary antibody control. (B) SPP1 expression in primary AML cells in 
response to 3 day in vitro culture with 4 ng/ml TGFβ1. SPP1 message was measured by qPCR in 5 samples. Bars represent fold upregulation 
of SPP1:B2M ratio compared to untreated controls.
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(P=0.02), for stemness in gene cluster 3 (P=0.033) and 
for tumour suppressors in both gene cluster 4 (P=0.009) 
and cluster 5 (P=0.03) (Supplementary Table 7). The four 
patient clusters were found to have significantly different 
proportions of highly expressed (>median) dormancy 
genes (1<2<3<4). The overall survival of intensively 
treated patients (n=127) was significantly worse in 
the cluster with the highest number of dormancy genes 
upregulated, i.e. patient cluster 4 (P=0.047, Figure 7B). 
This patient cluster contained a low proportion of FLT3 
mutations (P=0.051). It also contained all 6 FAB M6 and 
M7 cases, but was not enriched for a particular cytogenetic 
risk group, age or mutation in NPM1 (Supplementary 
Table 8). Intensively treated patients were dichotomised 
for one year survival. After excluding patients still alive 
but censored at less than one year, 106 patients remained 
in the dataset (61 alive, 45 dead). In this group the ten 
most differentially over-expressed genes in patient cluster 
4 were entered as potential predictors into multivariate 
(backward conditional) analysis. (Where there was more 
Figure 6: Adhesion molecule expression and in vitro adhesion of dormant TF-1a cells. (A) (i) Flow cytometric histograms 
illustrating CD61, CD51 and CD44 RFU (relative fluorescence units) in cycling TF-1a (blue-filled histogram), and dormant cells (pink-
filled histogram). Unfilled histograms represent isotype control fluorescence (in the case of CD61, the blue-filled histogram almost 
completely overlaps the isotype control). (ii) Summary plot (Mean + SD) for 3-6 independent assays. (B) The ratio of treated to untreated 
cells adherent to HS-5 stromal cells and to plates coated with fibronectin (Fn), hyaluronic acid (HA) or vitronectin (Vn), (Mean + SD for 
3-5 independent assays). *= p value<0.05, **= p value<0.01.
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than one probe per gene, only genes overexpressed in 
cluster 4 with at least 3 out of 4 probes were evaluated.) 
Expression levels of ITGB3, IL6ST and PTH2 were found 
to be significant prognostic factors of 1 year survival. 
Cytogenetic risk group, age and the presence of FLT3-ITD 
and NPM1 mutations were entered (Supplementary Table 
9), but were not found in the final model.
Figure 7: Dormancy signatures in TCGA patient samples. Analysis of samples from TCGA LAML database, which included 778 
probes for 341/376 genes (240 upregulated and 136 downregulated) of the dormant TF-1a cell signature. (A) Un-supervised hierarchical 
clustering of the probes in 149 AML patient samples. (B) Survival curve of AML patients from Patient Cluster 4 (gold line) compared to 
the combined Patient Clusters 1, 2 and 3 (green line).
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DISCUSSION
The establishment of an in vitro model of dormancy 
in AML cells was achieved by exploiting two prominent 
features of the dormant LIC niche in the bone marrow 
endosteal region, i.e. TGFβ1 production and low 
perfusion. TGFβ1 and rapamycin maintained excellent 
cell viability. In contrast, serum withdrawal, the most 
common approach to dormancy induction in suspension 
culture, exacts a heavy toll on leukaemia cell viability that 
might overshadow pathways of dormancy maintenance 
[8]. Our choice of three day cell conditioning with 
TGFβ1 and rapamycin before GEP was informed by 
work documenting many differences between transient 
(induction of dormancy) and long-term (dormancy 
maintenance) gene expression profiles in somatic cells 
[25, 26]. Our work focuses on consequences of a 3-day 
exposure to dormancy inducers and gives time for an 
equilibrium to be established between oncogene-driven 
growth and niche-driven quiescence, allowing us to 
describe likely characteristics of the chemoresistant LIC in 
the niche. The up-regulation of many genes in dormant TF-
1a cells despite the decrease in total RNA content indicates 
that dormancy is not merely an inhibition of proliferation 
or exit from the cell cycle, but is a phenomenon associated 
with active biological processes.
Upregulation of adhesion-related genes 
predominated in our model, and adhesion to bone 
marrow stromal cells, vitronectin and hyaluronic acid 
was also documented, supporting a role for recruitment 
and retention in specific microenvironments as a 
dominant characteristic of dormant LIC. Proliferating 
HSC and LSC display impairment of engraftment and 
reconstitution ability if compared to dormant counterparts 
[27, 28]. Enrichment for cell adhesion molecules has been 
documented in the HSC quiescence signature [29].
The most up-regulated gene in the dormancy 
signature was the osteopontin-coding gene SPP1. 
Osteopontin can function as adhesion protein, cytokine 
or chemokine and is implicated in HSC migration and 
self-renewal [30]. In a study of ALL cells, osteopontin 
caused the cells to exit the cell cycle and rendered them 
resistant to chemotherapy in vivo. The study did not 
identify a cell cycle effect for osteopontin in vitro and 
the authors concluded that osteopontin’s role was likely 
to be in regulating the homing of the leukaemia cells to 
the dormancy-inducing niche [31]. We demonstrated that 
osteopontin expression in AML blasts is dependent on 
tissue localisation, being high in biopsy material and low 
or negative in blasts from peripheral blood or bone marrow 
aspirates. Intracellular osteopontin can act as a bridging 
molecule for cytoskeletal re-arrangement and signal 
transduction [32, 33]. The cytoskeleton is likely affected 
by the increase in MYLK, which was the second most 
upregulated gene in our model. MYLK codes for a myosin 
light chain kinase that phosphorylates the microfilament 
protein NMM-II. MYH9, an isoform of NMM-II, is 
also upregulated in our model. This pathway is involved 
in sensing mechanical inputs from the extracellular 
environment and their transduction into intracellular 
signals and has many roles in the bone marrow niche [34]. 
MYLK overexpression has been reported in other models 
of dormancy initiation [26] and maintenance [25].
ITGB3 is an essential molecule for leukaemia cell 
propagation [17]. Its knockdown results in impairment of 
LSC homing (specifically to the bone marrow endosteal 
surface), downregulation of an LSC transcriptional 
programme, and induced differentiation [17]. ITGB3 is 
upregulated in the CD34+CD38- blast subset [35] and has 
been implicated in chemoresistance [36]. Osteopontin 
can augment ITGB3-mediated spreading and signal 
transduction [20].
A critical feature of the dormant cell is resistance 
to differentiation [25]. In this context GEP showed 
upregulation of PLXN1, MMP2, GRP-56, TIM3, 
MEIS1 and its target RGS1, and ITGA6, all previously 
associated with a stem or multipotent progenitor stage 
of normal haematopoiesis [37], and the model also 
showed downregulation of differentiation associated 
genes CEBPA and CSF2RB. Several genes upregulated 
in the TF1a dormancy model have been described in 
leukaemia initiating cells, but appear not to be crucial for 
maintenance of normal HSCs, e.g. CD44 [18], ITGB3 
[17], TIM3 (HAVCR2) [38] and IL3RA [39].
In addition to adhesion and stemness/inhibition of 
differentiation molecules we also documented tumour 
suppressor gene upregulation in TF-1a cells induced 
to dormancy (Figure 3). Strikingly, the only canonical 
cell cycle regulator upregulated in the model was the 
tumour suppressor CDKN2B (the cyclin-dependent 
kinase inhibitor p15). This gene is known to be 
epigenetically regulated, and is frequently mutated with 
a poor prognostic impact in AML [40]. In preliminary 
work we noted a transient induction of p57 by TGFβ1 
(data not shown), which had disappeared by 24 hours. 
This reinforces the point made above that initiation and 
maintenance of dormancy can be characterised by largely 
different transcriptional programs. BTG2 upregulation 
may be a common dormancy feature. Classified as a 
tumour suppressor [41], it has also been documented to 
be overexpressed in somatic dormant and sublethally 
damaged cells [42].
This study focused on the profile of dormancy 
induced by extrinsic factors. In the case of SPP1/
osteopontin, we documented strong expression only 
in bone marrow biopsies or mononuclear cell isolates 
that had been cultured with TGFβ1. Nevertheless it was 
interesting to establish that TCGA primary AML samples 
have varied expression of dormancy signature genes and 
that these distributed into clusters unrelated to cytogenetic 
risk group. ITGB3 (discussed above) was upregulated in 
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the dormancy model and also associated with poor one 
year survival in TCGA samples.
In this study, we demonstrated an in vitro approach 
mimicking key attributes of the LIC niche to characterize 
dormancy in CD34+CD38- AML cells. Genes identified in 
this model are candidates for investigations to establish 
potential targets for rooting out dormant AML cells.
MATERIALS AND METHODS
AML cell lines and cell culture
TF-1a cells were from The European Collection of 
Animal Cell Culture (Salisbury, UK) and were cultured 
in RPMI-1640 with 10% FCS and glutamine. Following 
treatments, cells were counted flow cytometrically 
using an internal standard as described [43]. Testing to 
authenticate the cell line was performed at the last passage 
of each thawed batch using multiplex short tandem repeat 
analysis (Powerplex 16, Promega, Southampton, UK). 
Mycoplasma testing was carried out routinely using the 
Mycoalert mycoplasma detection kit (Lonza, Rockland, 
USA) and following the manufacturer’s instructions.
Patient cells
The investigation was conducted on samples 
obtained with informed consent in accordance with ethical 
approval (Nottingham Research Ethics Committee 1) and 
Declaration of Helsinki and according to international 
guidelines and has been approved by the authors' 
institutional review board.
Indirect immunofluorescence assay for FOXO3a
Unmanipulated and TGFβ1-treated TF-1a cells were 
allowed to adhere on Poly-D-Lysine (PDL, p6407 Sigma)-
coated glass coverslips. They were stained with the 75D8 
anti-FOXO3A antibody from Cell Signalling Technologies. 
Images were acquired using an Olympus fluorescence 
microscope and visualised with ImageJ software.
Immunohistochemistry analysis of human bone 
marrow biopsies
The expression of osteopontin (OPN) was 
investigated by immunohistochemistry (IHC) analysis of 
formalin-fixed paraffin-embedded BM biopsy sections 
using standard procedures with mouse anti-human 
monoclonal anti-OPN (ab166709; abcam) and the X-Cell 
Plus Universal Polymer horseradish peroxidase (MP-
XCP-U25; Menarini Diagnostics) detection system.
Flow cytometry-based assays
Flow cytometry analyses were carried out using 
the FACS Canto II (BD Biosciences) with Diva software. 
Surface marker immunophenotyping was carried out 
using fluorochrome-conjugated anti-human monoclonal 
antibodies or isotype controls (BD Biosciences). The 
ALDEFLUORTM reagent kit (Stem Cell Technology 
#01700) was used to measure the intracellular activity 
of aldehyde dehydrogenase (ALDH). Cell viability was 
measured using Annexin V labelling (Trevigen Annexin 
V kit, #4830-250-K). Mouse anti-human anti-Ki-67-
FITC (#556026; BD Pharmingen, Oxford, UK) was 
used for detecting the nuclear protein Ki-67 in fixed and 
permeabilized AML cells. The protocol was based on a 
previously published method [44].
Adhesion to cells or to immobilised molecular 
substrates assays
HS-5 stromal cells [45] (American Type Culture 
Collection) were grown in DMEM with 10% FCS. 
Untreated and treated TF-1a cells were co-incubated 
with confluent HS-5 for three hours and detached by 
trypsinisation. TF-1a cells were identified and counted as 
described (Supplementary Figure 7).
96 well plates were coated with 10 μg/ml 
fibronectin, 10 μg/ml vitronectin or 1 mg/ml hyaluronic 
acid for 2 hours at 37°C, rinsed twice in PBS and dried 
overnight. TF-1a cells were allowed to attach for three 
hours and non-adherent cells were removed by washing 
with warm PBS. Attached cells were counted with a light 
microscope fitted with a wire grid (0.9X0.9 mm squares, 
quadruplicate plates).
Real-time quantitative polymerase chain 
reaction (qPCR) assay
Quantitative PCR was performed as previously 
described [46] using primer sequences as listed in 
Supplementary Table 10  and standardised with β2-
microglobulin (B2M) [47].
Global human genome gene expression profile 
(GEP) assay
RNA was processed according to the manufacturer’s 
protocol using the Agilent 2100 Bioanalyzer and Human 
Gene 2.1 Array Strips (#902114; Affymetrix) with the 
microarray system GeneAtlas from Affymetrix.
Data analysis
GEP data was analysed using Partek Genomics 
Suite 6.6 software. For the analysis of patient outcomes 
and groupings, the TCGA LAML data set GSE68833 
was downloaded from the Gene Expression Omnibus. 
Hierarchical clustering, using the Ward’s method was 
done with the Partek software. Additional analyses 
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were performed using the Statistical Package for Social 
Sciences, version 23 (SPSS, Chicago, IL, USA).
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